Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.85 Insider Own0.56% Shs Outstand72.22M Perf Week2.01%
Market Cap109.77M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float71.82M Perf Month-0.65%
Income-52.46M PEG- EPS next Q-0.20 Inst Own1.87% Short Float / Ratio0.50% / 0.32 Perf Quarter-24.75%
Sales0.00M P/S- EPS this Y-112.17% Inst Trans176.19% Short Interest0.36M Perf Half Y-8.43%
Book/sh0.20 P/B7.48 EPS next Y- ROA-77.99% Target Price14.30 Perf Year115.63%
Cash/sh0.36 P/C4.23 EPS next 5Y- ROE-152.82% 52W Range0.55 - 2.53 Perf YTD157.63%
Dividend- P/FCF- EPS past 5Y34.62% ROI-229.66% 52W High-39.92% Beta1.62
Dividend %- Quick Ratio1.86 Sales past 5Y0.00% Gross Margin- 52W Low178.90% ATR0.13
Employees49 Current Ratio1.96 Sales Q/Q- Oper. Margin0.00% RSI (14)49.53 Volatility8.50% 8.47%
OptionableYes Debt/Eq1.01 EPS Q/Q-86.65% Profit Margin- Rel Volume0.17 Prev Close1.45
ShortableYes LT Debt/Eq0.74 EarningsNov 20 BMO Payout- Avg Volume1.12M Price1.52
Recom1.00 SMA20-1.39% SMA50-3.28% SMA2009.57% Volume190,170 Change4.83%
Date Action Analyst Rating Change Price Target Change
May-18-17Upgrade Maxim Group Hold → Buy $1 → $3
Feb-13-17Initiated Rodman & Renshaw Buy $3
Aug-12-16Downgrade Maxim Group Buy → Hold $4 → $1
Aug-17-15Reiterated Maxim Group Buy $8 → $4
Jul-27-15Reiterated ROTH Capital Buy $10.50 → $7
Jun-22-15Initiated JMP Securities Mkt Outperform $5
Nov-21-23 03:45PM
Nov-20-23 07:00AM
Nov-13-23 07:00AM
Nov-02-23 03:12PM
Oct-31-23 09:00AM
11:38AM Loading…
Oct-30-23 11:38AM
Oct-12-23 07:00AM
Sep-28-23 07:00AM
Sep-19-23 07:00AM
Sep-14-23 05:36AM
Sep-11-23 07:00AM
Sep-05-23 06:04AM
Aug-31-23 08:18AM
Aug-30-23 07:00AM
Aug-22-23 07:00AM
02:34PM Loading…
Aug-07-23 02:34PM
Jul-18-23 03:22PM
Jul-17-23 07:00AM
Jun-29-23 02:00PM
Jun-07-23 05:25AM
May-24-23 07:00AM
May-17-23 07:00AM
May-04-23 01:56PM
Apr-25-23 07:00AM
Apr-17-23 11:00AM
Apr-04-23 08:21PM
Mar-24-23 07:15AM
Mar-23-23 11:42AM
Mar-22-23 07:00AM
Mar-15-23 07:00AM
07:00AM Loading…
Mar-06-23 07:00AM
Jan-04-23 07:00AM
Dec-20-22 12:36PM
Dec-05-22 04:00AM
Nov-28-22 04:30PM
Nov-15-22 07:00AM
Nov-10-22 04:30PM
Nov-04-22 04:30PM
Nov-03-22 09:11AM
Nov-02-22 09:21AM
Sep-27-22 07:00AM
Sep-19-22 08:00AM
Sep-15-22 12:38PM
Sep-12-22 07:00AM
Aug-18-22 07:47AM
Aug-16-22 07:00AM
Aug-11-22 07:00AM
Jun-29-22 08:00AM
Jun-28-22 07:00AM
Jun-16-22 07:00AM
May-12-22 10:16AM
May-11-22 07:00AM
May-05-22 07:00AM
Mar-17-22 08:55AM
Mar-16-22 07:00AM
Mar-10-22 07:00AM
Mar-03-22 07:00AM
Jan-31-22 04:20AM
Jan-24-22 07:00AM
Jan-18-22 07:00AM
Dec-17-21 07:00AM
Dec-15-21 07:00AM
Nov-18-21 07:00AM
Nov-12-21 07:16AM
Nov-04-21 09:15AM
Oct-13-21 08:30AM
Oct-06-21 04:38AM
Aug-18-21 07:00AM
Aug-12-21 09:30AM
Jun-30-21 08:58AM
Jun-04-21 09:04AM
May-26-21 07:00AM
May-20-21 07:00AM
May-04-21 08:56AM
Apr-15-21 07:14AM
Feb-23-21 07:45AM
Feb-17-21 07:00AM
Jan-28-21 11:31AM
Jan-22-21 04:15PM
Jan-19-21 09:42PM
Jan-07-21 09:28AM
Dec-16-20 07:15AM
Dec-02-20 10:45AM
Dec-01-20 08:34AM
Nov-23-20 08:15AM
Nov-19-20 10:08AM
Nov-18-20 07:00AM
Nov-16-20 10:06AM
Nov-13-20 09:42AM
Nov-11-20 10:10AM
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.